What Are the Worst Side Effects of Exemestane?

The worst side effects of exemestane center on what happens when estrogen drops to near-zero levels in the body: accelerated bone loss that raises fracture risk, persistent joint and muscle pain that drives many women to quit treatment, and unfavorable shifts in cholesterol. At a standard daily dose, exemestane suppresses circulating estrogen by roughly 85 to 95 percent in postmenopausal women, which is exactly what makes it effective against hormone-receptor-positive breast cancer but also what makes its side effects so pervasive. The drug’s side-effect profile is not subtle, and understanding which effects are most serious versus merely uncomfortable can help you and your oncologist weigh the tradeoffs.

How Exemestane Creates Its Side Effects

Exemestane is a steroidal aromatase inhibitor, meaning it permanently disables the aromatase enzyme that converts androgens into estrogen. Unlike the nonsteroidal inhibitors anastrozole and letrozole, which bind reversibly, exemestane locks onto the enzyme’s active site and destroys it for good. The body has to manufacture entirely new enzyme molecules to resume estrogen production. At the standard 25 mg daily dose, this translates to approximately 98 percent inactivation of peripheral aromatase activity and an 85 to 95 percent drop in circulating estrogen levels.¹ Nearly every bothersome side effect flows from that estrogen depletion, because estrogen does far more in the body than fuel cancer cells. It maintains bone density, lubricates joints, protects blood vessels, regulates cholesterol, and influences mood and cognition.

Bone Loss and Fracture Risk

Bone health is where exemestane poses perhaps its most measurable long-term danger. The Intergroup Exemestane Study, a large randomized trial that followed over 4,200 postmenopausal women with early breast cancer, found that switching from tamoxifen to exemestane lowered bone mineral density at the lumbar spine by about 2.7 percent and at the hip by about 1.4 percent within just six months. Both bone breakdown and bone formation markers increased in the exemestane group, but breakdown outpaced rebuilding. Over a median follow-up of about five years, 7 percent of women on exemestane experienced fractures compared with 5 percent on tamoxifen, translating to roughly 45 percent higher odds of breaking a bone.²

The researchers behind that trial were blunt in their assessment: the survival benefit of switching to exemestane “is achieved at the expense of some detriment to skeletal health.” That phrasing matters, because it frames bone loss not as a minor nuisance but as a calculable cost that you and your doctor need to weigh against the drug’s cancer-fighting advantage. For some women, particularly those who already have low bone density or osteoporosis before starting treatment, that math can be complicated.

Joint and Muscle Pain

If bone loss is the most dangerous musculoskeletal side effect, joint and muscle aches are the most disruptive in daily life. In the TEAM trial, which compared exemestane with tamoxifen in early breast cancer, women on exemestane reported significantly more bone and muscle aches than those on tamoxifen.³ The same pattern appeared in the TEXT and SOFT trials studying premenopausal women receiving ovarian suppression: exemestane produced more bone and joint pain complaints than tamoxifen.⁴

This pain is not trivial. When researchers tracked which symptom clusters most powerfully predicted women quitting their aromatase inhibitor early, musculoskeletal symptoms came out on top, with a hazard ratio of about 4.4 for early discontinuation. That means women whose joint and muscle pain worsened early in treatment were roughly four times as likely to stop therapy compared to women whose pain stayed stable.⁵ The mechanism behind aromatase-inhibitor-induced arthralgia is still not fully understood, which makes it harder to treat proactively.⁶

Cholesterol and Cardiovascular Shifts

Estrogen has a well-known protective effect on cholesterol. When exemestane strips it away, lipid profiles tend to move in an unfavorable direction. A 2024 meta-analysis of randomized controlled trials quantified the damage: exemestane raised LDL cholesterol (the “bad” kind) by about 4.4 mg/dL, lowered HDL cholesterol (the “good” kind) by about 6 mg/dL, and modestly decreased total cholesterol. Triglycerides dropped during the first year of treatment but that benefit didn’t persist beyond twelve months.⁷

The HDL decline is probably the more worrying finding. A sustained drop of 6 mg/dL in HDL may not sound dramatic, but HDL is already typically lower in postmenopausal women, and any further reduction nudges cardiovascular risk upward over the years of treatment. If you already have borderline cholesterol or existing heart disease risk factors, this is worth discussing with your oncologist and possibly a cardiologist. The lipid changes aren’t a reason to refuse exemestane on their own, but they are a reason to monitor bloodwork regularly during treatment.

Hot Flashes, Vaginal Dryness, and Sleep Problems

Exemestane intensifies many of the same symptoms that natural menopause produces, because it mimics a more extreme version of estrogen withdrawal. However, the pattern of which symptoms dominate can differ depending on what you’re comparing it to. In the TEAM trial’s first-year analysis, exemestane caused significantly more vaginal dryness and difficulty sleeping than tamoxifen, while tamoxifen produced worse hot flashes. Hot flash scores peaked at three months in both groups and then declined, but at twelve months tamoxifen users still reported a 33 percent increase from baseline in daily hot flashes versus just 7 percent with exemestane.³

In the TEXT and SOFT trials of premenopausal women, the pattern was similar: exemestane plus ovarian suppression caused more vaginal dryness, more loss of sexual interest, and more difficulty with sexual arousal than tamoxifen plus ovarian suppression, while tamoxifen was worse for hot flushes and sweats.⁴ The takeaway is that exemestane doesn’t necessarily cause more menopausal-type symptoms overall than tamoxifen; it causes different ones. Vaginal dryness and sexual dysfunction may be less discussed but can be just as distressing, and they tend to worsen rather than improve over the course of treatment.

Cognitive Effects

Many women on hormonal therapies worry about “chemo brain” and wonder whether exemestane contributes. The evidence here is actually more reassuring than you might expect. A study comparing cognitive function in postmenopausal breast cancer patients found that women who took exemestane alone showed no decline on any cognitive domain compared with healthy controls. In fact, the exemestane group showed a short-term improvement in information processing speed. The group that fared worse cognitively was patients who took tamoxifen first and then switched to exemestane; those women showed both short-term and long-term decline in verbal memory and executive function.⁸

This finding suggests that if you experience brain fog while taking exemestane, the drug itself may not be the primary culprit. The sequential combination with tamoxifen, cancer-related stress, sleep disruption, or other factors might be more to blame. It’s one of the few areas where exemestane’s track record looks genuinely better than anticipated.

Insulin Resistance and Body Composition

A less widely discussed side effect involves metabolic health. A study that carefully measured insulin sensitivity in postmenopausal breast cancer patients on aromatase inhibitors found that treated women were significantly more insulin resistant than controls, with about a 24 percent lower insulin sensitivity score. Peak insulin concentrations after a glucose challenge were also higher in the treated group.⁹ The effect was tied to higher body fat percentage, suggesting that the estrogen-depleted state promotes fat accumulation, which in turn drives insulin resistance.

For women with prediabetes or type 2 diabetes risk factors, this is meaningful. Aromatase inhibitor therapy can last five to ten years, and that’s a long time to be running at higher insulin levels. Regular glucose monitoring and attention to diet and exercise become more important, not less, during treatment.

Rare but Serious Reactions

Two categories of rare side effects deserve mention even though most women will never encounter them. The first is liver injury. Hepatotoxicity with aromatase inhibitors has rarely been reported in clinical trials, and as of one published review, only two previous case reports of exemestane-induced liver damage existed in the medical literature.¹⁰ That makes it exceptionally uncommon, but the cases that do occur tend to involve cholestatic injury, where bile flow from the liver is blocked. The symptoms include jaundice, dark urine, and itching. If you develop these while on exemestane, your doctor will likely check liver enzymes immediately.

The second rare reaction is severe dermatitis. Case reports describe patients developing a grade 3 eruptive, maculopapular rash while taking exemestane, sometimes poorly responsive to standard treatments and only resolving after the drug was stopped.¹¹ In at least one documented case, the patient also reacted to a second aromatase inhibitor (letrozole), suggesting the reaction may be class-related rather than unique to exemestane. Mild skin dryness is fairly common on aromatase inhibitors, but a widespread painful rash warrants prompt medical attention.

How Exemestane Compares to Other Aromatase Inhibitors and Tamoxifen

The side-effect landscape differs depending on what drug exemestane is being compared to. Against tamoxifen, the tradeoffs are reasonably clear: tamoxifen carries risks of blood clots and endometrial cancer that exemestane does not, while exemestane produces more joint pain, vaginal dryness, and bone loss than tamoxifen does.¹² The life-threatening risks tip toward tamoxifen; the daily-quality-of-life burden tips toward exemestane. For premenopausal women receiving ovarian suppression alongside either drug, the adverse event profiles are broadly similar to those seen in postmenopausal women, with about 30 to 31 percent experiencing grade 3 or 4 side effects regardless of which drug they were assigned.¹³

Against the other aromatase inhibitors, the differences are subtler. All three AIs cause joint pain, bone loss, and estrogen-depletion symptoms. But exemestane appears to lead to slightly higher discontinuation rates. A large 2025 study found that about 39 percent of women on exemestane stopped treatment within five years, compared with roughly 35 percent for both anastrozole and letrozole.¹⁴ Whether that reflects genuinely worse tolerability or other factors like prescribing patterns is still debated, but the gap is consistent across studies.

Why So Many Women Stop Treatment Early

Discontinuation rates for exemestane are strikingly high, and the reason matters. These are not women who forget their pills or can’t afford them; side effects are the driving force. In one study, about 31 percent of women on an aromatase inhibitor stopped therapy due to symptoms within the first year alone, and exemestane users were significantly more likely to quit than letrozole users.¹⁵ A separate analysis found that roughly 36 percent of exemestane-assigned patients discontinued before 24 months due to toxicity, compared with about 28 percent on letrozole.⁵

The symptom clusters that most reliably predicted quitting were musculoskeletal pain, cognitive complaints, mood changes, and concerns about weight and body image. Of those, musculoskeletal pain was the strongest predictor by a wide margin. This has practical implications: if you start exemestane and notice rapidly worsening joint pain in the first few months, flagging it early gives your team the best chance to intervene before the pain becomes intolerable and you stop treatment altogether. Staying on adjuvant endocrine therapy for the recommended duration is one of the most evidence-backed ways to prevent breast cancer recurrence, so managing side effects well enough to keep going matters enormously.

Managing the Most Troublesome Side Effects

Bone loss from aromatase inhibitors has the most established toolkit. Bisphosphonates and denosumab both prevent bone loss during treatment, and denosumab has demonstrated actual fracture reduction. Guidelines recommend weight-bearing exercise, adequate vitamin D, and sufficient calcium as routine measures for all women on aromatase inhibitors.¹⁶ A baseline bone density scan before or shortly after starting exemestane can help your oncologist decide whether bone-protective medication should begin right away or can wait.¹⁷

Joint pain management is less standardized. Exercise, particularly a combination of resistance and aerobic training, has some evidence behind it for reducing aromatase-inhibitor-related joint symptoms. Nonsteroidal anti-inflammatory drugs are used commonly, though their long-term risks make them imperfect for a problem that may persist for years. Some oncologists try switching from one aromatase inhibitor to another, since individual tolerance varies unpredictably. A woman who finds exemestane’s joint pain unbearable may do fine on letrozole, or vice versa, even though the drugs produce their effects through similar estrogen suppression.

For vaginal dryness and sexual symptoms, non-hormonal vaginal moisturizers and lubricants are the first-line approach, since systemic estrogen is generally off the table for women with hormone-receptor-positive breast cancer. Low-dose vaginal estrogen is sometimes considered in carefully selected patients after discussion with an oncologist, but this remains controversial. Hot flashes, when bothersome, can be addressed with certain antidepressants, gabapentin, or lifestyle modifications like dressing in layers and keeping the bedroom cool. Cholesterol should be monitored with periodic lipid panels, and statin therapy considered if levels climb into a concerning range during treatment.

Skin and Hair Changes

Beyond the rare severe dermatitis described earlier, many women on exemestane notice milder skin and hair changes. Thinning hair is a commonly reported complaint across all aromatase inhibitors, though it tends to be less dramatic than the hair loss seen with chemotherapy. Dry skin, brittle nails, and a general sense of accelerated aging of the skin are common enough that dermatologists who treat breast cancer patients recognize them as part of the aromatase inhibitor package. These effects are usually manageable with gentle skincare and moisturizers, but they can be psychologically wearing when layered on top of the other changes the drug causes. They rarely prompt discontinuation on their own, but when combined with joint pain, fatigue, and sexual symptoms, they contribute to the overall burden that makes many women question whether they can continue treatment for the full recommended course.